| Dr Amrita Kaur Bath, MD | |
|
4000 Cambridge St, Kansas City, KS 66160-5612 | |
| (913) 588-6009 | |
| Not Available |
| Full Name | Dr Amrita Kaur Bath |
|---|---|
| Gender | Female |
| Speciality | Rheumatology |
| Experience | 13 Years |
| Location | 4000 Cambridge St, Kansas City, Kansas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1578965802 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RR0500X | Internal Medicine - Rheumatology | 2019022405 (Missouri) | Secondary |
| 207RR0500X | Internal Medicine - Rheumatology | 04-42201 (Kansas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of Kansas Hospital | Kansas city, KS | Hospital |
| University Of Kansas Health System - St Francis Campus | Topeka, KS | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Kansas University Physicians, Inc. | 8921911587 | 1456 |
| Kansas University Physicians, Inc. | 8921911587 | 1456 |
News Archive
With the aging of nearly 80 million baby boomers, Alzheimer's disease is an impending epidemic that requires a new approach to prevention as well as management of the disease, according to a UC Santa Barbara professor who has co-authored a new book on the topic.
Early and appropriate treatment by a rheumatologist may decrease costly interventions —such as orthopedic surgery — in people with rheumatoid arthritis, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Chicago.
Berg, a biopharmaceutical company committed to uncovering health solutions through a data-driven, biological approach, presented clinical research from its trials using its cancer drug BPM 31510 on Phase Ib solid tumors and preclinical data on triple negative breast cancer, at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO), May 29 – June 2 in Chicago.
Researchers have identified a peptide and hormone that when administered to a specific area of the brain may reduce the desire for food. The study, which appears in the journal Neuropsychopharmacology, may one day lead to medications that treat obesity and binge eating disorders.
BioSante Pharmaceuticals, Inc. today announced that a New Drug Application (NDA) has been accepted for filing by the U.S. Food and Drug Administration (FDA) following submission in January 2011 by a subsidiary of Teva Pharmaceutical Industries Ltd.. The FDA has assigned a PDUFA date of November 14, 2011. The PDUFA date is the target date for the FDA to complete its review of the NDA.
› Verified 1 days ago
| Entity Name | Kansas University Physicians, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003858333 PECOS PAC ID: 8921911587 Enrollment ID: O20040401000328 |
News Archive
With the aging of nearly 80 million baby boomers, Alzheimer's disease is an impending epidemic that requires a new approach to prevention as well as management of the disease, according to a UC Santa Barbara professor who has co-authored a new book on the topic.
Early and appropriate treatment by a rheumatologist may decrease costly interventions —such as orthopedic surgery — in people with rheumatoid arthritis, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Chicago.
Berg, a biopharmaceutical company committed to uncovering health solutions through a data-driven, biological approach, presented clinical research from its trials using its cancer drug BPM 31510 on Phase Ib solid tumors and preclinical data on triple negative breast cancer, at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO), May 29 – June 2 in Chicago.
Researchers have identified a peptide and hormone that when administered to a specific area of the brain may reduce the desire for food. The study, which appears in the journal Neuropsychopharmacology, may one day lead to medications that treat obesity and binge eating disorders.
BioSante Pharmaceuticals, Inc. today announced that a New Drug Application (NDA) has been accepted for filing by the U.S. Food and Drug Administration (FDA) following submission in January 2011 by a subsidiary of Teva Pharmaceutical Industries Ltd.. The FDA has assigned a PDUFA date of November 14, 2011. The PDUFA date is the target date for the FDA to complete its review of the NDA.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Amrita Kaur Bath, MD 1300 Baltimore Ave Unit 2509, Kansas City, MO 64105-2331 Ph: (216) 218-5149 | Dr Amrita Kaur Bath, MD 4000 Cambridge St, Kansas City, KS 66160-5612 Ph: (913) 588-6009 |
News Archive
With the aging of nearly 80 million baby boomers, Alzheimer's disease is an impending epidemic that requires a new approach to prevention as well as management of the disease, according to a UC Santa Barbara professor who has co-authored a new book on the topic.
Early and appropriate treatment by a rheumatologist may decrease costly interventions —such as orthopedic surgery — in people with rheumatoid arthritis, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Chicago.
Berg, a biopharmaceutical company committed to uncovering health solutions through a data-driven, biological approach, presented clinical research from its trials using its cancer drug BPM 31510 on Phase Ib solid tumors and preclinical data on triple negative breast cancer, at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO), May 29 – June 2 in Chicago.
Researchers have identified a peptide and hormone that when administered to a specific area of the brain may reduce the desire for food. The study, which appears in the journal Neuropsychopharmacology, may one day lead to medications that treat obesity and binge eating disorders.
BioSante Pharmaceuticals, Inc. today announced that a New Drug Application (NDA) has been accepted for filing by the U.S. Food and Drug Administration (FDA) following submission in January 2011 by a subsidiary of Teva Pharmaceutical Industries Ltd.. The FDA has assigned a PDUFA date of November 14, 2011. The PDUFA date is the target date for the FDA to complete its review of the NDA.
› Verified 1 days ago
Micholee Beth Polsak, DO Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 3901 Rainbow Blvd, 6040 Delp, Ms 1020, Kansas University Physicians Inc, Kansas City, KS 66160 Phone: 913-588-3974 Fax: 913-588-6055 | |
Ira William Marsh, MD Rheumatology Medicare: May Accept Medicare Assignments Practice Location: 8929 Parallel Pkwy, Kansas City, KS 66112 Phone: 913-596-4000 | |
Dr. Tara L Lin, MD Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 3901 Rainbow Blvd, Kansas City, KS 66160 Phone: 913-588-6030 Fax: 913-588-4085 | |
Kristin N Fee, D.O. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 3901 Rainbow Blvd # Ms 2027, Kansas City, KS 66160 Phone: 913-588-3974 Fax: 913-588-6055 | |
Donald J. Mcsweyn, M.D. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 8919 Parallel Pkwy, Suite 580, Kansas City, KS 66112 Phone: 913-596-7224 Fax: 913-596-7257 | |
Dr. Dhanunjaya Lakkireddy, MD Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 3901 Rainbow Blvd, Suite#g600, Kansas City, KS 66160 Phone: 913-588-9600 Fax: 913-588-9770 | |
Archana Pareek, M.D. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 3901 Rainbow Blvd, 6040 Delp, Ms 1020, Division Of General And Geriatric Medicine, University, Kansas City, KS 66160 Phone: 913-588-6005 Fax: 913-588-3877 |